UK approves cannabidiol-based medication for new condition

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a cannabidiol based medicine, EPIDYOLEX, for use in controlling seizures associated with tuberous sclerosis complex. The approval follows data from a Phase 3 safety and efficacy study and was made through the European Commission Decision Reliance Procedure, meaning that EPIDYOLEX can now be used to treat this condition in all 27 EU countries as well as in England, Scotland, Wales, and Northern Ireland.